作者
Sarika Madari, Raphael Golebiowski, Meghna P Mansukhani, Bhanu Prakash Kolla
发表日期
2021/1/1
来源
Neurotherapeutics
卷号
18
期号
1
页码范围
44-52
出版商
Elsevier
简介
Insomnia is a highly prevalent condition associated with significant morbidity, reduction in quality of life, and increase in healthcare costs, and is a risk factor for multiple physical and mental disorders. The primary treatment modality is cognitive behavioral therapy for insomnia (CBT-I) but this is associated with difficulties with access and higher cost as well as poor response in some patients. Therefore, pharmacotherapy for insomnia is common and hypnotic agents are among the most frequently prescribed medications in the United States. Older medications for insomnia are limited by their side effect burden and narrow therapeutic window. Newer hypnotics, on the other hand, have been shown to have a better safety profile and longer term efficacy. While some studies have shown that long-term hypnotic use is associated with adverse outcomes, the current evidence is equivocal. The decision to treat chronic …
引用总数
学术搜索中的文章
S Madari, R Golebiowski, MP Mansukhani, BP Kolla - Neurotherapeutics, 2021